LianBio (LIAN) Stock Price, News & Analysis

Company Overview

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.

Key Stats

• Today's Range: $0.29 to $0.30
• 50-Day Range: $0.28 to $0.36
• 52-Week Range: $0.27 to $4.99
• Volume: 25,043 shs
• Average Volume: 1.04 million shs
• Market Capitalization: $31.12 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.50
• Consensus Rating: Reduce

LianBio Stock Analysis - MarketRank™

LianBio scored higher than 22% of companies evaluated by MarketBeat, and ranked 863rd out of 952 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.8 / 5
• Analyst Rating: Reduce

Consensus Rating

LianBio has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no buy ratings, 1 hold rating, and 1 sell rating.

Amount of Analyst Coverage

LianBio has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for LianBio are expected to decrease in the coming year, from $2.40 to ($0.86) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of LianBio is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of LianBio is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

LianBio has a P/B Ratio of 0.11. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for LIAN.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

LianBio does not currently pay a dividend.

Dividend Growth

LianBio does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for LIAN.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

MarketBeat Follows

1 people have added LianBio to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, LianBio insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 7.59% of the stock of LianBio is held by insiders.

Percentage Held by Institutions

74.85% of the stock of LianBio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

LIAN Stock Analysis - Frequently Asked Questions

How have LIAN shares performed this year?

LianBio's stock was trading at $4.47 on January 1st, 2024. Since then, LIAN shares have decreased by 93.6% and is now trading at $0.2879.
View the best growth stocks for 2024 here.

How were LianBio's earnings last quarter?

LianBio (NASDAQ:LIAN) released its earnings results on Monday, March, 27th. The company reported ($0.17) earnings per share for the quarter, beating analysts' consensus estimates of ($0.27) by $0.10.

When did LianBio IPO?

LianBio (LIAN) raised $325 million in an initial public offering (IPO) on the week of November 1st 2021. The company issued 20,300,000 shares at $16.00 per share. Goldman Sachs, Jefferies and BofA Securities acted as the underwriters for the IPO.

How do I buy shares of LianBio?

Shares of LIAN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of LianBio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that LianBio investors own include Arista Networks (ANET), NVIDIA (NVDA), ServiceNow (NOW), Broadcom (AVGO), Novo Nordisk A/S (NVO), PACCAR (PCAR) and Super Micro Computer (SMCI).

Company Calendar

• Last Earnings: 3/27/2023
• Today: 11/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:LIAN
• CUSIP: N/A
• CIK: 1831283
• Web: www.lianbio.com
• Phone: 609-486-2308
• Fax: N/A
• Employees: 110
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $3.50
• High Stock Price Target: $4.00
• Low Stock Price Target: $3.00
• Potential Upside/Downside: +1,115.5%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.81)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 0.12
• P/E Growth: N/A
• Net Income: $-110,290,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -33.17%
• Return on Assets: -30.19%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.06
• Quick Ratio: 10.06

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.71 per share
• Price / Book: 0.11

Miscellaneous

• Outstanding Shares: 108,063,000
• Free Float: 99,861,000
• Market Cap: $31.12 million
• Optionable: Not Optionable
• Beta: 0.23